GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » MicroTech Medical (Hangzhou) Co Ltd (HKSE:02235) » Definitions » Intrinsic Value: Projected FCF

MicroTech Medical (Hangzhou) Co (HKSE:02235) Intrinsic Value: Projected FCF : HK$0.00 (As of Jan. 19, 2025)


View and export this data going back to 2021. Start your Free Trial

What is MicroTech Medical (Hangzhou) Co Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2025-01-19), MicroTech Medical (Hangzhou) Co's Intrinsic Value: Projected FCF is HK$0.00. The stock price of MicroTech Medical (Hangzhou) Co is HK$5.28. Therefore, MicroTech Medical (Hangzhou) Co's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for MicroTech Medical (Hangzhou) Co's Intrinsic Value: Projected FCF or its related term are showing as below:

HKSE:02235's Price-to-Projected-FCF is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.64
* Ranked among companies with meaningful Price-to-Projected-FCF only.

MicroTech Medical (Hangzhou) Co Intrinsic Value: Projected FCF Historical Data

The historical data trend for MicroTech Medical (Hangzhou) Co's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MicroTech Medical (Hangzhou) Co Intrinsic Value: Projected FCF Chart

MicroTech Medical (Hangzhou) Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Intrinsic Value: Projected FCF
- - - - -

MicroTech Medical (Hangzhou) Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only - - - - -

Competitive Comparison of MicroTech Medical (Hangzhou) Co's Intrinsic Value: Projected FCF

For the Medical Devices subindustry, MicroTech Medical (Hangzhou) Co's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MicroTech Medical (Hangzhou) Co's Price-to-Projected-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, MicroTech Medical (Hangzhou) Co's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where MicroTech Medical (Hangzhou) Co's Price-to-Projected-FCF falls into.



MicroTech Medical (Hangzhou) Co Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



MicroTech Medical (Hangzhou) Co  (HKSE:02235) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

MicroTech Medical (Hangzhou) Co's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=5.28/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MicroTech Medical (Hangzhou) Co Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of MicroTech Medical (Hangzhou) Co's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


MicroTech Medical (Hangzhou) Co Business Description

Traded in Other Exchanges
N/A
Address
No. 108 Liuze Street, Cangqian Street, Yuhang District, Zhejiang Province, Hangzhou, CHN
MicroTech Medical (Hangzhou) Co Ltd is engaged in the research and development and manufacturing and commercialization of diabetes management, providing both diabetes treatment and diabetes monitoring medical devices to improve diabetes management in China and the rest of the world. The company derives a majority of its revenue from China.
Executives
Qm32 Limited 2101 Beneficial owner
Qiming Venture Partners V, L.p. 2201 Interest of corporation controlled by you
Qiming Gp V, L.p. 2201 Interest of corporation controlled by you
Qiming Corporate Gp V, Ltd. 2201 Interest of corporation controlled by you
Lilly Asia Ventures Fund Ii, L.p. 2201 Interest of corporation controlled by you
Lilly Asia Ventures Fund Gp, L.p. 2201 Interest of corporation controlled by you
Lav Evergreen (hong Kong) Co., Limited 2101 Beneficial owner
Lav Corporate Gp, Ltd. 2201 Interest of corporation controlled by you
Zheng Pan
Master Summer Limited 2201 Interest of corporation controlled by you
Cdbi Partners Gp, Ltd 2201 Interest of corporation controlled by you
Cdbi Partners Fund Ii, L.p. 2201 Interest of corporation controlled by you
Cdbi Partners Fund I, L.p. 2201 Interest of corporation controlled by you
Cdbi Gp, Ltd 2201 Interest of corporation controlled by you
Cd Capital Healthcare Fund V, L.p. 2201 Interest of corporation controlled by you

MicroTech Medical (Hangzhou) Co Headlines

No Headlines